OBJECTIVES: A variety of inflammatory cytokines have been demonstrated to participate in tumorigenesis and progression. Secretory leukocyte protease inhibitor (SLPI) has been demonstrated to show a broad-spectrum of anti-inflammatory effects. This study investigates the expression of SLPI in human pancreatic cancer tissues and cells as well as its biological effects in human pancreatic cancer cells. METHODS: Reverse transcription-polymerase chain reaction, immunohistochemistry, and Western blot were used to detect SLPI mRNA and protein levels in human pancreatic cancer tissues, adjacent tissues, and pancreatic cancer Bxpc-3 and Panc-1 cells. Knockout of SLPI expression was established by recombinant viral vector expressing short hairpin RNA (shRNA) targeting SLPI. Cell viability was analyzed by MTT assay. Cell apoptosis was detected by Hochest33258 staining and flow cytometry assay. RESULTS: Higher SLPI expression was observed in pancreatic tissues, Bxpc-3 cells, and Panc-1 cells compared to the peritumoral tissues (p < 0.01). SLPI expression in Bxpc-3 and Panc-1 cells was effectively silenced by shRNA (p < 0.001). Silencing of SLPI expression significantly reduced cell viability, inhibited cell proliferation, and induced cell apoptosis (p < 0.001). CONCLUSIONS: Abnormal over-expression of SLPI in pancreatic cancer cells may be associated with the development of disease through its roles in promoting cancer cell survival and proliferation as well as anti-apoptosis. SLPI can be used as a target for developing targeted therapy of pancreatic cancer.
OBJECTIVES: A variety of inflammatory cytokines have been demonstrated to participate in tumorigenesis and progression. Secretory leukocyte protease inhibitor (SLPI) has been demonstrated to show a broad-spectrum of anti-inflammatory effects. This study investigates the expression of SLPI in humanpancreatic cancer tissues and cells as well as its biological effects in humanpancreatic cancer cells. METHODS: Reverse transcription-polymerase chain reaction, immunohistochemistry, and Western blot were used to detect SLPI mRNA and protein levels in humanpancreatic cancer tissues, adjacent tissues, and pancreatic cancer Bxpc-3 and Panc-1 cells. Knockout of SLPI expression was established by recombinant viral vector expressing short hairpin RNA (shRNA) targeting SLPI. Cell viability was analyzed by MTT assay. Cell apoptosis was detected by Hochest33258 staining and flow cytometry assay. RESULTS: Higher SLPI expression was observed in pancreatic tissues, Bxpc-3 cells, and Panc-1 cells compared to the peritumoral tissues (p < 0.01). SLPI expression in Bxpc-3 and Panc-1 cells was effectively silenced by shRNA (p < 0.001). Silencing of SLPI expression significantly reduced cell viability, inhibited cell proliferation, and induced cell apoptosis (p < 0.001). CONCLUSIONS: Abnormal over-expression of SLPI in pancreatic cancer cells may be associated with the development of disease through its roles in promoting cancer cell survival and proliferation as well as anti-apoptosis. SLPI can be used as a target for developing targeted therapy of pancreatic cancer.
Authors: Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban Journal: CA Cancer J Clin Date: 2013-07-15 Impact factor: 508.702
Authors: Byungwoo Ryu; Jessa Jones; Natalie J Blades; Giovanni Parmigiani; Michael A Hollingsworth; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2002-02-01 Impact factor: 12.701
Authors: Paul Glen; Nigel B Jamieson; Donald C McMillan; Ross Carter; Clem W Imrie; Colin J McKay Journal: Pancreatology Date: 2006-07-13 Impact factor: 3.996
Authors: Nick Devoogdt; Gholamreza Hassanzadeh Ghassabeh; Jing Zhang; Lea Brys; Patrick De Baetselier; Hilde Revets Journal: Proc Natl Acad Sci U S A Date: 2003-05-05 Impact factor: 11.205
Authors: Ge Ma; Teresa Greenwell-Wild; Kejian Lei; Wenwen Jin; Jennifer Swisher; Neil Hardegen; Carl T Wild; Sharon M Wahl Journal: J Exp Med Date: 2004-11-15 Impact factor: 14.307
Authors: Charalambos Gustav Antoniades; Wafa Khamri; Robin D Abeles; Leonie S Taams; Evangelos Triantafyllou; Lucia A Possamai; Christine Bernsmeier; Ragai R Mitry; Alistair O'Brien; Derek Gilroy; Robert Goldin; Michael Heneghan; Nigel Heaton; Wayel Jassem; William Bernal; Diego Vergani; Yun Ma; Alberto Quaglia; Julia Wendon; Mark Thursz Journal: Hepatology Date: 2014-02-28 Impact factor: 17.425
Authors: Shuhong Hao; Xiaoyuan Du; Yang Song; Ming Ren; Qiwei Yang; Ao Wang; Qingyu Wang; Haiyue Zhao; Zhenwu Du; Guizhen Zhang Journal: Oncol Lett Date: 2018-03-01 Impact factor: 2.967
Authors: Jacklyn N Hellwege; Shirley B Russell; Scott M Williams; Todd L Edwards; Digna R Velez Edwards Journal: Ann Hum Genet Date: 2018-02-27 Impact factor: 1.670
Authors: Tomasz Stępień; Mateusz Brożyna; Krzysztof Kuzdak; Ewelina Motylewska; Jan Komorowski; Henryk Stępień; Hanna Ławnicka Journal: Dis Markers Date: 2017-01-31 Impact factor: 3.434